Dilated Cardiomyopathy – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Dilated Cardiomyopathy – Drugs In Development, 2024 report and make more profitable business decisions.
Dilated cardiomyopathy (DCM) is a condition in which the heart’s ability to pump blood is decreased because the heart’s main pumping chamber, the left ventricle, is enlarged and weakened. Symptoms include fatigue and weakness, shortness of breath (dyspnea), lightheadedness, dizziness or fainting, persistent cough or wheezing, lack of appetite, sudden weight gain from fluid retention, and swelling (edema) in legs, ankles, and feet. Risk factors include family history, alcoholism, hypertension, cocaine abuse, and metabolic disorders, such as thyroid disease or diabetes.
The Dilated Cardiomyopathy drugs in development market research report provide comprehensive information on the therapeutics under development for Dilated Cardiomyopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dilated Cardiomyopathy and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Dilated Cardiomyopathy | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 38 molecules, with 37 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Dilated Cardiomyopathy therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Dilated Cardiomyopathy pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Dilated Cardiomyopathy treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Avery Therapeutics IncBerlin Cures Holding AG
BioMarin Pharmaceutical Inc
Bristol-Myers Squibb Co
Cardior Pharmaceuticals GmbH
CellServe GmbH
Constant Therapeutics LLC
DiNAQOR AG
Dynomics Inc
Help Therapeutics
iHeart Japan Corp
Modalis Therapeutics Corp
Novo Nordisk AS
Nuevocor Pte Ltd
Olagenesis Corp
Osaka University Hospital
Phlox Therapeutics BV
Rocket Pharmaceuticals Inc
Secretome Therapeutics
Shanghai Juvensis Therapeutics Biotechnology Co Ltd
Shionogi & Co Ltd
Solid Biosciences Inc
Tenaya Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Dilated Cardiomyopathy reports